GlassScriptPhysician profile
Ryan W Urbas
NPI 1720344849
$7,258.05
in general payments reported to CMS, 2019-2025
30 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $916 · 2023: $2,041 · 2024: $2,204 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,269 · Education: $72.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,268.87 |
| Education | $72.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,422.30 | 2022-2025 | Rinvoq, Skyrizi, Viberzi |
| Celgene Corporation | $955.78 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $657.99 | 2023-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $579.17 | 2022-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $424.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $409.77 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.30 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $331.79 | 2022-2025 | Dupixent |
| Genzyme Corporation | $278.47 | 2022-2025 | |
| Qol Medical, LLC | $225.92 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $219.39 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $182.37 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $152.36 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $150.75 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $133.12 | 2022-2024 | Ocaliva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $119.05 | 2022-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $102.51 | 2022-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $95.74 | 2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $77.99 | 2022-2023 | Rebyota |
| Evoke Pharma, INC. | $56.43 | 2023-2025 | Gimoti |
| Gilead Sciences, INC. | $47.87 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $41.36 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $35.26 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $30.63 | 2023 | Sutab |
| Organon LLC | $27.25 | 2023 | Hadlima |
| Redhill Biopharma INC. | $20.45 | 2023 | Aemcolo, Talicia, Movantik |
| Inspire Medical Systems, INC. | $19.48 | 2024 | Inspire |
| Nestle Healthcare Nutrition INC. | $18.52 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.51 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.06 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Urbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.